Summary
Report Scope
The report analyzes the trends in the global emerging drugs market. It includes global revenue ($ billions) for the base year of 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented by molecule type (small molecules, biologics and biosimilars, other molecule types), by product type (branded drugs and generic drugs), by therapeutic application (oncology, immunology, cardiovascular, other therapeutic applications), and by end users (hospitals and specialty clinics, pharmacies, and other end users. The regions covered in this study are North America, Europe, Asia-Pacific, and the rest of the World (RoW), with market analysis.
The report focuses on the trends and challenges that affect the market. It includes an analysis of the competitive landscape, with the ranking of leading companies. It offers company profiles that cover financials, product portfolios, and recent developments.
Report Includes
- An overview and analysis of the global emerging drugs market
- Analyses of global market trends, with revenue data for 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the current market size and revenue growth prospects, accompanied by a market share analysis by molecule type, product type, therapeutic application, end user, and region
- Facts and figures pertaining to market dynamics, including key drivers, restraints, challenges, opportunities, and the impact of macroeconomic factors
- Insights derived from Porter’s Five Forces analysis, along with an assessment of market structure and competitive intensity
- Review of the regulatory landscape and approval pathways influencing the development and commercialization of emerging drugs
- Discussion of emerging technologies and developments, including advancements in small molecules, biologics, biosimilars, and cell and gene therapies
- Patent review highlighting key granted and published patents related to emerging drug development
- Analysis of the competitive landscape, including company market share rankings, strategic initiatives, and venture funding activity
- Overview of sustainability trends and ESG developments in the global emerging drugs market
- Company profiles of the leading players
ページTOPに戻る
Table of Contents
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Regional Analysis
Emerging Technologies
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors
Porter’s Five Forces Analysis
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Regulatory Acceleration and Supportive Innovation Pathways
Rising Burden of Chronic Diseases and Ageing Population
Increasing R&D Investment and Sustained Capital Formation
Market Restraints
Complexity of Manufacturing and Supply Chain Challenges
Pricing and Reimbursement Pressures, Limiting Market Access and Revenue Realization
Market Opportunities
Increasing Focus on Rare Diseases and Orphan Drug Development
Growth of Advanced Modalities: Cell, Gene, and RNA Therapies
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologiesand Developments
Key Takeaways
Next-Generation Therapeutic Modalities and Platform Technologies
Artificial Intelligence (AI)-Driven Drug Discovery and Clinical Development Optimization
Precision Medicine, Biomarkers, and Companion Diagnostics
Advanced Manufacturing and Scalable Production Technologies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Molecule Type
Key Takeaways
Small Molecules
Biologics and Biosimilars
Other Molecule Types
Market Analysis by Product Type
Key Takeaways
Branded Drugs
Generic Drugs
Market Analysis by Therapeutic Application
Key Takeaways
Oncology
Immunology
Cardiovascular
Other Therapeutic Applications
Market Analysis by End User
Key Takeaways
Hospitals and Specialty Clinics
Pharmacies
Other End Users
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Analysis
Strategic Initiatives
Mergers and Acquisitions
Collaborations
Chapter 8 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
AMGEN INC.
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
VERTEX PHARMACEUTICALS INC.
ページTOPに戻る
List of Tables/Graphs
List of Tables
Summary Table : Global Market for Emerging Drugs, by Region, Through 2030
Table 1 : Global Market for Emerging Drugs, by Molecule Type, Through 2030
Table 2 : Global Market for Emerging Small Molecules Drugs, by Region, Through 2030
Table 3 : Global Market for Emerging Biologics and Biosimilars Drugs, by Region, Through 2030
Table 4 : Global Market for Emerging Other Molecule Types Drugs, by Region, Through 2030
Table 5 : Global Market for Emerging Drugs, by Product Type, Through 2030
Table 6 : Global Market for Emerging Branded Drugs, by Region, Through 2030
Table 7 : Global Market for Emerging Generic Drugs, by Region, Through 2030
Table 8 : Global Market for Emerging Drugs, by Therapeutic Application, Through 2030
Table 9 : Global Market for Emerging Oncology Drugs, by Region, Through 2030
Table 10 : Global Market for Emerging Immunology Drugs, by Region, Through 2030
Table 11 : Global Market for Emerging Cardiovascular Drugs, by Region, Through 2030
Table 12 : Global Market for Other Emerging Therapeutic Applications Drugs, by Region, Through 2030
Table 13 : Global Market for Emerging Drugs, by End User, Through 2030
Table 14 : Global Market for Emerging Drugs for Hospitals and Specialty Clinics, by Region, Through 2030
Table 15 : Global Market for Emerging Drugs for Pharmacies, by Region, Through 2030
Table 16 : Global Market for Emerging Drugs for Other End Users, by Region, Through 2030
Table 17 : Global Market for Emerging Drugs , by Region, Through 2030
Table 18 : North American Market for Emerging Drugs, by Molecule Type, Through 2030
Table 19 : North American Market for Emerging Drugs, by Product Type, Through 2030
Table 20 : North American Market for Emerging Drugs, by Therapeutic Application, Through 2030
Table 21 : North American Market for Emerging Drugs, by End User, Through 2030
Table 22 : European Market for Emerging Drugs, by Molecule Type, Through 2030
Table 23 : European Market for Emerging Drugs, by Product Type, Through 2030
Table 24 : European Market for Emerging Drugs, by Therapeutic Application, Through 2030
Table 25 : European Market for Emerging Drugs, by End User, Through 2030
Table 26 : Asia-Pacific Market for Emerging Drugs, by Molecule Type, Through 2030
Table 27 : Asia-Pacific Market for Emerging Drugs, by Product Type, Through 2030
Table 28 : Asia-Pacific Market for Emerging Drugs, by Therapeutic Application, Through 2030
Table 29 : Asia-Pacific Market for Emerging Drugs, by End User, Through 2030
Table 30 : RoW Market for Emerging Drugs, by Molecule Type, Through 2030
Table 31 : RoW Market for Emerging Drugs, by Product Type, Through 2030
Table 32 : RoW Market for Emerging Drugs, by Therapeutic Application, Through 2030
Table 33 : RoW Market for Emerging Drugs, by End User, Through 2030
Table 34 : Global Ranking of Companies in Emerging Drugs Market, 2024
Table 35 : Mergers and Acquisitions in Global Emerging Drugs Market, 2023–2026
Table 36 : Collaborations in Global Emerging Drugs Market, 2023–2025
Table 37 : Information Sources Used for this Report
Table 38 : Abbreviations Used in this Report
Table 39 : Amgen Inc.: Company Snapshot
Table 40 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 41 : Amgen Inc.: Product Portfolio
Table 42 : Amgen Inc.: News/Key Developments, 2023–2026
Table 43 : Bristol-Myers Squibb Co.: Company Snapshot
Table 44 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 45 : Bristol-Myers Squibb Co.: Product Portfolio
Table 46 : Bristol-Myers Squibb Co.: News/Key Developments, 2024 and 2025
Table 47 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 48 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 49 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 50 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023–2025
Table 51 : Johnson & Johnson: Company Snapshot
Table 52 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 53 : Johnson & Johnson: Product Portfolio
Table 54 : Johnson & Johnson: News/Key Developments, 2023–2026
Table 55 : Lilly USA LLC.: Company Snapshot
Table 56 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 57 : Lilly USA LLC.: Product Portfolio
Table 58 : Lilly USA LLC.: News/Key Developments, 2024–2026
Table 59 : Merck & Co. Inc.: Company Snapshot
Table 60 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 61 : Merck & Co. Inc.: Product Portfolio
Table 62 : Merck & Co. Inc.: News/Key Developments, 2023–2025
Table 63 : Novartis AG: Company Snapshot
Table 64 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 65 : Novartis AG: Product Portfolio
Table 66 : Novartis AG: News/Key Developments, 2024–2026
Table 67 : Pfizer Inc.: Company Snapshot
Table 68 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 69 : Pfizer Inc.: Product Portfolio
Table 70 : Pfizer Inc.: News/Key Developments, 2023–2025
Table 71 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 72 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 73 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 74 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2025
Table 75 : Vertex Pharmaceuticals Inc.: Company Snapshot
Table 76 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 77 : Vertex Pharmaceuticals Inc.: Product Portfolio
Table 78 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2025
